Paraoxonases activities and polymorphisms in elderly and old-age diseases: An overview

Antioxidants

Volumn 8, Issue 5, 2019, Pages

  Levy, Débora ^a   Reichert, Cadiele Oliana ^a   Bydlowski, Sérgio Paulo ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b CNPq   (Brazil)

Author keywords

Aging; Atherosclerosis; Cancer; Diabetes; Heart disease; Lipid peroxidation; Lipids; Neurodegenerative diseases; Paraoxonase; PON

Indexed keywords

EID: 85066761588     PISSN: None     EISSN: 20763921     Source Type: Journal    
DOI: 10.3390/antiox8050118     Document Type: Article

References (210)

1. Salmon, A.B.; Richardson, A.; Pérez, V.I. Update on the oxidative stress theory of aging: Does oxidative stress play a role in aging or healthy aging? Free Radic. Biol. Med. 2010, 48, 642-655.
2. Jacob, K.D.; Hooten, N.N.; Trzeciak, A.R.; Evans, M.K. Markers of oxidant stress that are clinically relevant in aging and age-related disease. Mech. Ageing Dev. 2013, 134, 139-157.
3. Liguori, I.; Russo, G.; Curcio, F.; Bulli, G.; Aran, L.; Della-Morte, D.; Gargiulo, G.; Testa, G.; Cacciatore, F.; Bonaduce, D.; et al. Oxidative stress, aging, and diseases. Clin. Interv. Aging 2018, 13, 757-772.
4. Bydlowski, S.P.; Yunker, R.L.; Subbiah, M.T. Ontogeny of 6-keto-PGF1α synthesis in rabbit aorta and the effect of premature weaning. Am. J. Physiol. 1987, 252, 14-21.
5. Levy, D.; de Melo, T.C.; Ohira, B.Y.; Fidelis, M.L.; Ruiz, J.L.; Rodrigues, A.; Bydlowski, S.P. Oxysterols selectively promote short-term apoptosis in tumor cell lines. Biochem. Biophys. Res. Commun. 2018, 505, 1043-1049.
6. Levy, D.; de Melo, T.C.; Ruiz, J.L.; Bydlowski, S.P. Oxysterols and mesenchymal stem cell biology. Chem. Phys. Lipids 2017, 207, 223-230.
7. Rosa-Fernandes, L.; Maselli, L.M.; Maeda, N.Y.; Palmisano, G.; Bydlowski, S.P. Outside-in, inside-out: Proteomic analysis of endothelial stress mediated by 7-ketocholesterol. Chem. Phys. Lipids 2017, 207, 231-238.
8. Fernandes, L.R.; Stern, A.C.B.; Cavaglieri, R.C.; Nogueira, F.C.S.; Domont, G.; Palmisano, G.; Bydlowski, S.P. 7-Ketocholesterol overcomes drug resistance in chronic myeloid leukemia cell lines beyondMDR1mechanism. J. Proteom. 2017, 151, 12-23.
9. Silva, S.F.; Levy, D.; Ruiz, J.L.M.; de Melo, T.C.; Isaac, C.; Fidelis, M.L.; Rodrigues, A.; Bydlowski, S.P. Oxysterols in adipose tissue-derived mesenchymal stem cell proliferation and death. J. Steroid. Biochem. Mol. Biol. 2017, 169, 164-175.
10. Ferreira, A.K.; Freitas, V.M.; Levy, D.; Ruiz, J.L.M.; Bydlowski, S.P.; Rici, R.E.G.; Filho, O.M.R.; Chierice, G.O.; Maria, D.A. Anti-angiogenic and anti-metastatic activity of synthetic phosphoethanolamine. PLoS ONE 2013, e57937.
11. Bydlowski, S.P.; Yunker, R.L.; Rymaszewski, Z.; Subbiah, M.T.R. Coffee extracts inhibit platelet-aggregation in vivo and in vitro. Int. J. Vitam. Nutr. Res. 1987, 57, 217-223.
12. Ruiz, J.L.M.; Fernandes, L.R.; Levy, D.; Bydlowski, S.P. Interrelationship between ATP-binding cassette transporters and oxysterols. Biochem. Pharmacol. 2013, 86, 80-88.
13. do Amaral, V.F.; Bydlowski, S.P.; Peranovich, T.C.; Navarro, P.A.; Subbiah, M.T.R.; Ferriani, R.A. Lipid peroxidation in the peritoneal fluido f infertile women with peritoneal endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2005, 119, 72-75.
14. Aviram, M.; Rosenblat, M.; Bisgaier, C.L.; Newton, R.S.; Primo-Parmo, S.L.; La Du, B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A Possible Peroxidative Role Paraoxonase. J. Clin. Investig. 1998, 101, 1581-1590.
15. Ng, C.J.; Wadleigh, D.J.; Gangopadhyay, A.; Hama, S.; Grijalva, V.R.; Navab, M.; Fogelman, A.M.; Reddy, S.T. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 2001, 276, 44444-44449.
16. Draganov, D.I.; Stetson, P.L.;Watson, C.E.; Billecke, S.S.; La Du, B.N. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J. Biol. Chem. 2000, 275, 33435-33442.
17. Moya, C.; Máñez, S. Paraoxonases: Metabolic role and pharmacological projection. Naunyn. Schmiedebergs Arch. Pharmacol. 2018, 391, 349-359.
18. Kanasi, E.; Ayilavarapu, S.; Jones, J. The aging population: Demographics and the biology of aging. Periodontology 2000, 72, 13-18.
19. Davalli, P.; Mitic, T.; Caporali, A.; Lauriola, A.; D’Arca, D. ROS, Cell Senescence, and Novel Molecular Mechanisms in Aging and Age-Related Diseases. Oxid. Med. Cell. Longev. 2016, 3565127.
20. Squier, T.C. Oxidative stress and protein aggregation during biological aging. Exp. Gerontol. 2001, 36, 1539-1550.
21. Ademowo, O.S.; Dias, H.K.I.; Burton, D.G.A.; Griffiths, H.R. Lipid (per) oxidation in mitochondria: An emerging target in the ageing process? Biogerontology 2017, 18, 859-879.
22. El Assar, M.; Ângulo, J.; Rodríguez-Mañas, L. Oxidative stress and vascular inflammation in aging. Free Radic. Biol. Med. 2013, 65, 380-401.
23. Sadowska-Bartosz, I.; Bartosz, G. Effect of antioxidants supplementation on aging and longevity. Biomed. Res. Int. 2014, 404680.
24. Mahrooz, A. Pharmacological Interactions of Paraoxonase 1 (PON1): A HDL-Bound Antiatherogenic Enzyme. Curr. Clin. Pharmacol. 2016, 11, 259-264.
25. Menini, T.; Gugliucci, A. Paraoxonase 1 in neurological disorders. Redox Rep. 2014, 19, 49-58.
26. Liu, H.H.; Li, J.J. Aging and dyslipidemia: A review of potential mechanisms. Ageing Res. Rev. 2015, 19, 43-52.
27. Mau, T.; Yung, R. Adipose tissue inflammation in aging. Exp. Gerontol. 2018, 105, 27-31.
28. Bacchetti, T.; Ferretti, G.; Sahebkar, A. The role of paraoxonase in cancer. Semin. Cancer Biol. 2017, 1044, 30191-30198.
29. Primo-Parmo, S.L.; Sorenson, R.C.; Teiber, J.; La Du, B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996, 33, 498-507.
30. Sorenson, R.C.; Primo-Parmo, S.L.; Camper, A.S.; La Du, B.N. The genetic mapping and gene structure of mouse paraoxonase/arylesterase. Genomics 1995, 30, 431-438.
31. Motti, C.; Dessì, M.; Gnasso, A.; Irace, C.; Indigeno, P.; Angelucci, C.B.; Bernardini, S.; Fucci, G.; Federici, G.; Cortese, C. A multiplex PCR-based DNA assay for the detection of paraoxonase gene cluster polymorphisms. Atherosclerosis 2001, 158, 35-40.
32. Walker, C.H. The classification of esterases which hydrolyse organophosphates: Recent developments. Chem. Biol. Interact. 1993, 87, 17-24.
33. Furlong, C.E.; Li, W.F.; Brophy, V.H.; Jarvik, G.P.; Richter, R.J.; Shih, D.M.; Lusis, A.J.; Costa, L.G. The PON1 gene and detoxication. Neurotoxicology 2000, 21, 581-587.
34. Mackness, M.I. ‘A’-esterases. Enzymes looking for a role? Biochem. Pharmacol. 1989, 38, 385-390.
35. Costa, L.G.; Richter, R.J.; Li, W.F.; Cole, T.; Guizzetti, M.; Furlong, C.E. Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity. Biomarkers 2003, 8, 1-12.
36. Draganov, D.I.; Teiber, J.F.; Speelman, A.; Osawa, Y.; Sunahara, R.; La Du, B.N. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 2005, 46, 1239-1247.
37. Li, X.C.; Wang, C.; Mulchandani, A.; Ge, X. Engineering Soluble Human Paraoxonase 2 for Quorum Quenching. ACS Chem. Biol. 2016, 11, 3122-3131.
38. Huang, D.;Wang, Y.; He, Y.;Wang, G.;Wang,W.; Han, X.; Sun, Y.; Lin, L.; Shan, B.; Shen, G.; et al. Paraoxonase 3 is involved in the multi-drug resistance of esophageal cancer. Cancer Cell Int. 2018, 8, 168.
39. Shunmoogam, N.; Naidoo, P.; Chilton, R. Paraoxonase (PON)-1: A brief overview on genetics, structure, polymorphisms and clinical relevance. Vasc. Health Risk Manag. 2018, 14, 137-143.
40. Rosenblat, M.; Gaidukov, L.; Khersonsky, O.; Vaya, J.; Oren, R.; Tawfik, D.S.; Aviram, M. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 2006, 281, 7657-7665.
41. Deakin, S.; Moren, X.; James,R.W. Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis 2005, 179, 17-25.
42. Fuhrman, B.; Volkova, N.; Aviram, M. Paraoxonase 1 (PON1) is present in postprandial chylomicrons. Atherosclerosis 2005, 180, 55-61.
43. Gugliucci, A.; Menini, T. Paraoxonase 1 and HDL maturation. Clin. Chim. Acta. 2015, 439, 5-13.
44. Diffenderfer, M.R.; Schaefer, E.J. The composition and metabolism of large and small LDL. Curr. Opin. Lipidol.2014, 25, 221-226.
45. Mackness, B.; Mackness, M. Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. Adv. Exp. Med. Biol. 2010, 660, 143-151.
46. Kunutsor, S.K.; Bakker, S.J.; James, R.W.; Dullaart, R.P. Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies. Atherosclerosis 2016, 245, 143-154.
47. Selek, S.; Aslan, M.; Horoz, M.; Gur, M.; Erel, O. Oxidative status and serum PON1 activity in beta-thalassemia minor. Clin. Biochem. 2007, 40, 287-291.
48. Takci, Z.; Bilgili, S.G.; Karadag, A.S.; Kucukoglu, M.E.; Selek, S.; Aslan, M. Decreased serum paraoxonase and arylesterase activities in patients with rosacea. J. Eur. Acad. Dermatol. Venereol. 2015, 29, 367-370.
49. Yildiz, A.; Gur, M.; Demirbag, R.; Yilmaz, R.; Akyol, S.; Aslan, M.; Erel, O. Paraoxonase and arylesterase activities in untreated dipper and non-dipper hypertensive patients. Clin. Biochem. 2008, 41, 779-784.
50. Camuzcuoglu, H.; Toy, H.; Cakir, H.; Celik, H.; Erel, O. Decreased paraoxonase and arylesterase activities in the pathogenesis of future atherosclerotic heart disease in women with gestational diabetes mellitus. J. Womens Health (Larchmt) 2009, 18, 1435-1439.
51. Maselli, L.M.; da Cunha, J.; Gutierrez, E.B.; Maranhão, R.C.; Spada, C.; Bydlowski, S.P. Human paraoxonase-1 activity is related to the number of CD4+ T-cells and is restored by antiretroviral therapy in HIV-1-infected individuals. Dis. Markers 2014, 2014, 480201.
52. Da Cunha, J.; Maselli, L.M.; Treitinger, A.; Monteiro, A.M.; Gidlund, M.; Maranhão, R.C.; Spada, C.; Bydlowski, S.P. Serumlevels of IgG antibodies against oxidized LDL and atherogenic indices in HIV-1-infected patients treated with protease inhibitors. Clin. Chem. Lab. Med. 2013, 51, 371-378.
53. Berrougui, H.; Khalil, A. Age-associated decrease of high-density lipoprotein-mediated reverse cholesterol transport activity. Rejuvenation Res. 2009, 12, 117-126.
54. 4. Oxid. Med. Cell Longev. 2014, 2014, 893212.
55. Marsillach, J.; Camps, J.; Ferré, N.; Beltran, R.; Rull, A.; Mackness, B.; Mackness, M.; Joven, J. Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterol. 2009, 9, 3.
56. Stipanuk, M.H. Sulfur amino acid metabolism: Pathways for production and removal of homocysteine and cysteine. Annu. Ver. Nutr. 2004, 24, 539-577.
57. Finkelstein, J.D. Pathways and regulation of homocysteine metabolism in mammals. Semin. Thromb. Hemost.2000, 26, 219-225.
58. Perła-Kaján, J.; Jakubowski, H. Paraoxonase 1 and homocysteine metabolism. Amino Acids 2012, 43, 1405-1417.
59. Faria-Neto, J.R.; Chagas, A.C.P.; Bydlowski, S.P.; Lemos Neto, S.P.A.; Chamone, D.A.; Ramirez, J.A.F.; da Luz, P.L. Hyperhomocystinemia in patients with coronary artery disease. Braz. J. Med. Biol. Res. 2006, 39, 455-463.
60. Genoud, V.; Quintana, P.G.; Gionco, S.; Baldessari, A.; Quintana, I. Structural changes of fibrinogen molecule mediated by the N-homocysteinylation reaction. J. Thromb. Thrombolysis 2018, 45, 66-76.
61. Eren, E.; Ellidag, H.Y.; Aydin, O.; Yılmaz, N. Homocysteine, Paraoxonase-1 and Vascular Endothelial Dysfunction: Omnibus viis Romam Pervenitur. J. Clin. Diagn. Res. 2014, 8, 1-4.
62. AnandBabu, K.; Bharathidevi, S.R.; Sripriya, S.; Sem, P.; Prakash, V.J.; Bindu, A.; Viswanathan, N.; Angayarkanni, N. Serum Paraoxonase activity in relation to lipid profile in Age-related Macular Degeneration patients. Exp. Eye Res. 2016, 152, 100-112.
63. Jamroz-Wísniewska, A.; Bełtowski, J.; Bartosik-Psujek, H.; Wójcicka, G.; Rejdak, K. Processes of plasma protein N-homocysteinylation in multiple sclerosis. Int. J. Neurosci. 2017, 127, 709-715.
64. Borowczyk, K.; Shih, D.M.; Jakubowski, H. Metabolism and neurotoxicity of homocysteine thiolactone in mice: Evidence for a protective role of paraoxonase 1. J. Alzheimers Dis. 2012, 30, 225-231.
65. Humbert, R.; Adler, D.A.; Disteche, C.M.; Hassett, C.; Omiecinski, C.J.; Furlong, C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 1993, 3, 73-76.
66. Adkins, S.; Gan, K.N.; Mody, M.; La Du, B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A and B allozymes. Am. J. Hum. Genet. 1993, 52, 598-608.
67. Mackness, B.; Mackness, M.I.; Arrol, S.; Turkie, W.; Durrington, P.N. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br. J. Pharmacol. 1997, 122, 265-268.
68. Cherki, M.; Berrougui, H.; Isabelle, M.; Cloutier, M.; Koumbadinga, G.A.; Khalil, A. Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging. Exp. Gerontol. 2007, 42, 815-824.
69. Mochizuki, H.; Scherer, S.W.; Xi, T.; Nickle, D.C.; Majer, M.; Huizenga, J.J.; Tsui, L.C.; Prochazka, M. Human PON2 gene at 7q21.3: Cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 1998, 213, 149-157.
70. Devarajan, A.; Bourquard, N.; Hama, S.; Navab, M.; Grijalva, V.R.; Morvardi, S.; Clarke, C.F.; Vergnes, L.; Reue, K.; Teiber, J.F.; et al. Paraoxonase 2 deficiency alters mitochondrial function and exacerbates the development of atherosclerosis. Antioxid. Redox Signal. 2011, 14, 341-351.
71. Rom, O.; Aviram, M. Paraoxsonase2 (PON2) and oxidative stress involvement in pomegranate juice protection against cigarette smoke-induced macrophage cholesterol accumulation. Chem. Biol. Interact. 2016, 259, 394-400.
72. Aviram, M.; Rosenblat, M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic. Biol. Med. 2004, 37, 1304-1316.
73. Altenhöfer, S.; Witte, I.; Teiber, J.F.; Wilgenbus, P.; Pautz, A.; Li, H.; Daiber, A.; Witan, H.; Clement, A.M.; Förstermann, U.; et al. One enzyme, two functions: PON2 prevents mitochondrial superoxide formation and apoptosis independent from its lactonase activity. J. Biol. Chem. 2010, 285, 24398-24403.
74. Garrick, J.M.; Dao, K.; de Laat, R.; Elsworth, J.; Cole, T.B.; Marsillach, J.; Furlong, C.E.; Costa, L.G. Developmental expression of paraoxonase 2. Chem. Biol. Interact. 2016, 259, 168-174.
75. Furlong, C.E.; Marsillach, J.; Jarvik, G.P.; Costa, L.G. Paraoxonases-1, -2 and -3: What are their functions? Chem. Biol. Interact. 2016, 259, 51-62.
76. Rajkovic, M.G.; Rumora, L.; Barisic, K. The paraoxonase 1, 2 and 3 in humans. Biochem. Med. (Zagreb) 2011, 21, 122-130.
77. Giordano, G.; Tait, L.; Furlong, C.E.; Cole, T.B.; Kavanagh, T.J.; Costa, L.G. Gender differences in brain susceptibility to oxidative stress are mediated by levels of paraoxonase-2 expression. Free Radic. Biol. Med.2013, 58, 98-108.
78. Précourt, L.P.; Marcil, V.; Ntimbane, T.; Taha, R.; Lavoie, J.C.; Delvin, E.; Seidman, E.G.; Beaulieu, J.F.; Levy, E. Antioxidative properties of paraoxonase 2 in intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 303, 623-634.
79. Levy, E.; Trudel, K.; Bendayan, M.; Seidman, E.; Delvin, E.; Elchebly, M.; Lavoie, J.C.; Precourt, L.P.; Amre, D.; Sinnett, D. Biological role, protein expression, subcellular localization, and oxidative stress response of paraoxonase 2 in the intestine of humans and rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293, 1252-1261.
80. Costa, L.G.; de Laat, R.; Dao, K.; Pellacani, C.; Cole, T.B.; Furlong, C.E. Paraoxonase-2 (PON2) in brain and its potential role in neuroprotection. Neurotoxicology 2014, 43, 3-9.
81. Shi, S.; Buck, T.M.; Kinlough, C.L.; Marciszyn, A.L.; Hughey, R.P.; Chalfie, M.; Brodsky, J.L.; Kleyman, T.R. Regulation of the epithelial Na(+) channel by paraoxonase-2. J. Biol. Chem. 2017, 292, 15927-15938.
82. Reddy, S.T.; Wadleigh, D.J.; Grijalva, V.; Ng, C.; Hama, S.; Gangopadhyay, A.; Shih, D.M.; Lusis, A.J.; Navab, M.; Fogelman, A.M. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated byoxidized lipids. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 542-547.
83. Shi, J.; Zhang, S.; Tang, M.; Liu, X.; Li, T.; Han, H.;Wang, Y.; Guo, Y.; Zhao, J.; Li, H.; et al. Possible association between Cys311Ser polymorphism of paraoxonase 2 gene and late-onset Alzheimer’s disease in Chinese. Brain Res. Mol. Brain Res. 2004, 120, 201-204.
84. Rosenblat, M.; Draganov, D.; Watson, C.E.; Bisgaier, C.L.; La Du, B.N.; Aviram, M. Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 468-474.
85. Li, X.; Cao, J.;Wang, J.; Song, H.; Ji, G.; Dong, Q.;Wei, C.; Cao, Y.;Wang, B.; Zhu, B.; et al. PON2 and ATP2B2 gene polymorphisms with noise-induced hearing loss. J. Thorac. Dis. 2016, 8, 430-438.
86. Sanghera, D.K.; Manzi, S.; Minster, R.L.; Shaw, P.; Kao, A.; Bontempo, F.; Kamboh, M.I. Genetic variation in the paraoxonase-3 (PON3) gene is associated with serum PON1 activity. Ann. Hum. Genet. 2008, 72, 72-81.
87. Cronin, S.; Greenway, M.J.; Prehn, J.H.; Hardiman, O. Paraoxonase promoter and intronic variants modify risk of sporadic amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 2007, 78, 984-986.
88. Nozue, T.; Yamamoto, S.; Tohyama, S.; Fukui, K.; Umezawa, S.; Onishi, Y.; Kunishima, T.; Hibi, K.; Terashima, M.; Michishita, I. A predictor of atheroma progression in patients achieving very low levels of low-density lipoprotein cholesterol. Am. J. Cardiovasc. Dis. 2013, 3, 255-263.
89. Akbas, H.S.; Basyigit, S.; Suleymanlar, I.; Kemaloglu, D.; Koc, S.; Davran, F.; Demir, I.; Suleymanlar, G. The assessment of carotid intima media thickness and serumparaoxonase-1 activity in Helicobacter pylori positive subjects. Lipids Health Dis. 2010, 30, 92.
90. Mete, R.; Oran, M.; Alpsoy, S.; Gunes, H.; Tulubas, F.; Turan, C.; Topcu, B.; Aydin, M.; Yildirim, O. Carotid intima-media thickness and serum paraoxonase-1 activity inpatients with Helicobacter pylori. Eur. Rev. Med. Pharmacol. Sci. 2013, 17, 2884-2889.
91. Aragonès, G.; García-Heredia, A.; Guardiola, M.; Rull, A.; Beltrán-Debón, R.; Marsillach, J.; Alonso-Villaverde, C.; Mackness, B.; Mackness, M.; Pedro-Botet, J.; et al. Serum paraoxonase-3 concentration in HIV-infected patients. Evid. A Prot. Role Against Oxid. J. Lipid Res. 2012, 53, 168-174.
92. Feleciano, D.R.; Kirstein, J. Collapse of redox homeostasis during aging and stress. Mol. Cell. Oncol. 2015, 3, e1091060.
93. Rongo, C. Better to burn out than it is to rust: Coordinating cellular redox states during aging and stress. EMBO J. 2015, 34, 2310-2311.
94. Ogłodek, E.A. The role of PON-1, GR, IL-18, and OxLDL in depression with and without posttraumatic stress disorder. Pharmacol. Rep. 2017, 69, 837-845.
95. Johnston-Carey, H.K.; Pomatto, L.C.; Davies, K.J. The Immunoproteasome in oxidative stress, aging, and disease. Crit. Ver. Biochem. Mol. Biol. 2015, 51, 268-281.
96. Pradas, I.; Jové, M.; Huynh, K.; Puig, J.; Ingles, M.; Borras, C.; Viña, J.; Meikle, P.J.; Pamplona, R. Exceptional human longevity is associated with a specific plasma phenotype of ether lipids. Redox Biol. 2019, 21, 101-127.
97. Wei, M.; Brandhorst, S.; Shelehchi, M.; Mirzaei, H.; Cheng, C.W.; Budniak, J.; Groshen, S.; Mack, W.J.; Guen, E.; Di Biase, S.; et al. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci. Transl. Med. 2017, 9, e8700.
98. Lee, Y.S.; Park, C.O.; Noh, J.Y.; Jin, S.; Lee, N.R.; Noh, S.; Lee, J.H.; Lee, K.H. Knockdown of paraoxonase 1 expression influences the ageing of human dermal microvascular endothelial cells. Exp. Dermatol. 2012, 21, 682-687.
99. Christiansen, L.; Bathum, L.; Frederiksen, H.; Christensen, K. Paraoxonase 1 polymorphisms and survival. Eur. J. Hum. Genet. 2004, 12, 843-847.
100. Caliebe, A.; Kleindorp, R.; Blanché, H.; Christiansen, L.; Puca, A.A.; Rea, I.M.; Slagboom, E.; Flachsbart, F.; Christensen, K.; Rimbach, G.; et al. No or only population-specific effect of PON1 on human longevity: A comprehensive meta-analysis. Ageing Res. Rev. 2010, 9, 238-244.
101. Li, Y.; Liang, G.; Shi, L.; Liang, X.; Long, B.; Qin, J.; Zhang, Z. Paraoxonase-1 (PON1) rs662 Polymorphism and Its Association with Serum Lipid Levels and Longevity in the Bama Zhuang Population. Med. Sci. Monit. 2016, 22, 5154-5162.
102. Tanhapour, M.; Miri, A.; Vaisi-Raygani, A.; Bahrehmand, F.; Kiani, A.; Rahimi, Z.; Pourmotabbed, T.; Shakiba, E. Synergism between apolipoprotein E "4 allele and paraoxonase (PON1) 55-M allele is associated with risk of systemic lúpus erythematosus. Clin. Rheumatol. 2018, 37, 971-977.
103. Mehdi, M.M.; Rizvi, S.I. Human plasma paraoxonase 1 (PON1) arylesterase activity during aging: Correlation with susceptibility of LDL oxidation. Arch. Med. Res. 2012, 43, 438-443.
104. Kubben, N.; Misteli, T. Shared molecular and cellular mechanisms of premature ageing and ageing-associated diseases. Nat. Rev. Mol. Cell Biol. 2017, 18, 595-609.
105. Jęśko, H.; Wencel, P.; Strosznajder, R.P.; Strosznajder, J.B. Sirtuins and Their Roles in Brain Aging and Neurodegenerative Disorders. Neurochem. Res. 2017, 42, 876-890.
106. van de Ven, R.A.H.; Santos, D.; Haigis, M.C. Mitochondrial Sirtuins and Molecular Mechanisms of Aging. Trends Mol. Med. 2017, 23, 320-331.
107. Wang, Y.; He, J.; Liao, M.; Hu, M.; Li, W.; Ouyang, H.; Wang, X.; Ye, T.; Zhang, Y.; Ouyang, L. An overview of Sirtuins as potential therapeutic target: Structure, function and modulators. Eur. J. Med. Chem. 2019, 161, 48-77.
108. Cazzaniga, A.; Locatelli, L.; Castiglioni, S.; Maier, J.A.M. The dynamic adaptation of primary human endothelial cells to simulated microgravity. FASEB J. 2019, fj201801586RR.
109. Breitenstein, A.; Wyss, C.A.; Spescha, R.D.; Franzeck, F.C.; Hof, D.; Riwanto, M.; Hasun, M.; Akhmedov, A.; von Eckardstein, A.; Maier, W.; et al. Peripheral blood monocyte Sirt1 expression is reduced in patients with coronary artery disease. PLoS ONE 2013, 8, e53106.
110. Kilic, U.; Gok, O.; Erenberk, U.; Dundaroz, M.R.; Torun, E.; Kucukardali, I.; Elibol-Can, B.; Uysal, O.; Dundar, T. A Remarkable Age-Related Increase in SIRT1 Protein Expression against Oxidative Stress in Elderly: SIRT1 Gene Variants and Longevity in Human. PLoS ONE 2015, 10, e0117954.
111. Rognoni, A.; Cavallino, C.; Veia, A.; Bacchini, S.; Rosso, R.; Facchini, M.; Secco, G.G.; Lupi, A.; Nardi, F.; Rametta, F.; et al. Pathophysiology of Atherosclerotic Plaque Development. Cardiovasc. Hematol. Agents Med. Chem. 2015, 13, 10-13.
112. Wang, J.C.; Bennett, M. Aging and atherosclerosis: Mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ. Res. 2012, 111, 245-259.
113. Camaré, C.; Pucelle, M.; Nègre-Salvayre, A.; Salvayre, R. Angiogenesis in the atherosclerotic plaque. Redox Biol. 2017, 12, 18-34.
114. Steinberg, D. The LDL modification hypothesis of atherogenesis: An update. J. Lipid Res. 2009, 50, 376-381.
115. Childs, B.G.; Baker, D.J.; Wijshake, T.; Conover, C.A.; Campisi, J.; van Deursen, J.M. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science 2016, 354, 472-477.
116. Balder, J.W.; Staels, B.; Kuivenhoven, J.A. Pharmacological interventions in human HDL metabolism. Curr. Opin. Lipidol. 2013, 24, 500-509.
117. Alique, M.; Luna, C.; Carracedo, J.; Ramírez, R.LDLbiochemical modifications: Alink between atherosclerosis and aging. Food Nutr. Res. 2015, 59, e29240.
118. März, W.; Kleber, M.E.; Scharnagl, H.; Speer, T.; Zewinger, S.; Ritsch, A.; Parhofer, K.G.; von Eckardstein, A.; Landmesser, U.; Laufs, U. HDL cholesterol: Reappraisal of its clinical relevance. Clin. Res. Cardiol. 2017, 106, 663-675.
119. Estrada-Luna, D.; Ortiz-Rodriguez, M.A.; Medina-Briseño, L.; Carreón-Torres, E.; Izquierdo-Veja, J.�?.; Sharma, A.; Cancino-Díaz, J.C.; Pérez-Méndez, O.; Belefant-Miller, H.; Betanzos-Cabrera, G. Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease. Molecules 2018, 23, 2730.
120. Pirillo, A.; Catapano, A.L. Pitavastatin and HDL: Effects on plasma levels and function(s). Atheroscler. Suppl.2017, 2, 1-9.
121. Mackness, M.I.; Durrington, P.N. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995, 115, 243-253.
122. Ikhlef, S.; Berrougui, H.; Simo, O.K.; Zerif, E.; Khalil, A. Human paraoxonase 1 overexpression in mice stimulates HDL cholesterol efflux and reverse cholesterol transport. PLoS ONE 2017, 12, e0173385.
123. Ng, C.J.; Hama, S.Y.; Bourquard, N.; Navab, M.; Reddy, S.T. Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice. Mol. Genet. Metab. 2006, 89, 368-3673.
124. Ng, C.J.; Bourquard, N.; Hama, S.Y.; Shih, D.; Grijalva, V.R.; Navab, M.; Fogelman, A.M.; Reddy, S.T. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 1368-1374.
125. Mackness, B.; Mackness, M. The antioxidant properties of high-density lipoproteins in atherosclerosis. Panminerva Med. 2012, 54, 83-90.
126. Mackness, M.; Mackness, B. Current aspects of paraoxonase-1 research. In The HDL Handbook-Biological Functions and Clinical Implications, 2nd ed.; Komoda, T., Ed.; Academic Press: London, UK, 2014; pp. 273-291.
127. Mackness, M.I.; Arrol, S.; Durrington, P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991, 286, 152-154.
128. Mackness, M.I.; Abbott, C.A.; Arrol, S.; Durrington, P.N. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem. J. 1993, 294, 829-835.
129. Mackness, M.I.; Arrol, S.; Abbott, C.A.; Durrington, P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993, 104, 129-135.
130. Mackness, B.; Hunt, R.; Durrington, P.N.; Mackness, M.I. Increased immune localization of paraoxonase, clusterin and apolipoprotein AI in the human artery wall with progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 1997, 17, 1233-1238.
131. Mackness, B.; Durrington, P.N.; Mackness, M.I. Human serum paraoxonase. Gen. Pharmacol. 1998, 31, 329-336.
132. Mackness, B.; Mackness, M.I.; Arrol, S.; Turkie, W.; Durrington, P.N. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 1998, 423, 57-60.
133. Mackness, B.; Davies, G.K.; Turkie, W.; Lee, E.; Roberts, D.H.; Hill, E.; Roberts, C.; Durrington, P.N.; Mackness, M.I. Paraoxonase Status Coron. Heart Disease. Are Act. Conc. More Important Than Genotype? Arterioscler. Thromb. Vasc. Biol. 2001, 21, 1451-1457.
134. Mackness, B.; Durrington, P.; McElduff, P.; Yarnell, J.; Azam, N.;Watt, M.; Mackness, M. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003, 107, 2775-2779.
135. Mackness, B.; Durrington, P.; Povey, A.; Thomson, S.; Dippnall, M.; Mackness, M.; Smith, T.; Cherry, N. Paraoxonase and susceptibility to organophosphorus poisoning in farmers dipping sheep. Pharmacogenetics 2003, 13, 81-88.
136. Mackness, B.; Hine, D.; Liu, Y.; Mastorikou, M.; Mackness, M. Paraoxonase 1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem. Biophys. Res. Commun. 2004, 318, 680-683.
137. Mackness, B.; Quarck, R.; Verreth, W.; Mackness, M.; Holvoet, P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler. Thromb. Vasc. 2006, 26, 1545-1550.
138. White, C.R.; Anantharamaiah, G.M. Cholesterol Reduction and Macrophage Function: Role of Paraoxonases. Curr. Opin. Lipidol 2017, 28, 397-402.
139. Liu, Y.; Mackness, B.; Mackness, M. Comparison of the ability of paraoxonases 1 and 3 to attenuate the in vitro oxidation of low-density lipoprotein and reduce macrophage oxidative stress. Free Radic. Biol. Med.2008, 45, 743-748.
140. Soran, H.; Schofield, J.D.; Durrington, P.N. Antioxidant properties of HDL. Front. Pharmacol. 2015, 6, 1-6.
141. Bhattacharyya, T.; Nicholls, S.J.; Topol, E.J.; Zhang, R.; Yang, X.; Schmitt, D.S.; Fu, X.; Shao, M.; Brennan, D.M.; Ellis, S.G.; et al. Relationship of paraoxonase1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008, 299, 1265-1276.
142. Karlsson, H.; Kontush, A.; James, R.W. Functionality of HDL: Antioxidation and etoxifying effects. Handb. Exp. Pharmacol. 2015, 224, 207-228.
143. Mackness, M.; Mackness, B. Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. Gene 2015, 567, 12-21.
144. Shih, D.M.; Yu, J.M.; Vergnes, L.; Dali-Youcef, N.; Champion, M.D.; Devarajan, A.; Zhang, P.; Castellani, L.W.; Brindley, D.N.; Jamey, C.; et al. PON3 knockout mice are susceptible to obesity, gallstone formation, andatherosclerosis. FASEB J. 2015, 29, 1185-1197.
145. Lesnefsky, E.J.; Hoppel, C.L. Ischemia-reperfusion injury in the aged heart: Role of mitochondria. Arch. Biochem. Biophys. 2003, 420, 287-297.
146. Eghbali, M.; Reddy, S.T. Paraoxonase 2 protects against acute myocardial ischemia-reperfusion injury by modulating mitochondrial function and oxidative stress via the PI3K/Akt/GSK-3β RISK pathway. J. Mol. Cell. Cardiol. 2019, 154-164.
147. Ansari, S.A.; Pendurthi, U.R.; Rao, L.V.M. The lipid peroxidation product4-hydroxy-2-nonenal induces tissue factor decryption via ROS generation and the thioredoxin system. Blood Adv. 2017, 1, 2399-2413.
148. Ebert, J.; Wilgenbus, P.; Teiber, J.F.; Jurk, K.; Schwierczek, K.; Döhrmann, M.; Xia, N.; Li, H.; Spiecker, L.; Ruf,W.; et al. Paraoxonase-2 regulates coagulation activation through endothelial tissue factor. Blood 2018, 131, 161-2172.
149. Deng, Z.; Xiang, H.; Gao, W. Significant association between paraoxonase 1 rs662 polymorphism and coronary heart disease: A meta-analysis in the Chinese population. Herz 2018, 1, 1-9.
150. Chi, D.S.; Ling, W.H.; Ma, J.; Xia, M.; Hou, M.J.; Wang, Q.; Zhu, H.L.; Tang, Z.H.; Yu, X.P. Study of the association between paraoxonase1 55 Met/Leu, paraoxonase2 148 Ala/Gly and manganese superoxide dismutase (MnSOD) 9 Ala/Val genetic polymorphisms and coronary heart disease. Zhonghua Liu Xing Bing Xue Za Zhi 2006, 27, 808-813.
151. Marchegiani, F.; Spazzafumo, L.; Provinciali, M.; Cardelli, M.; Olivieri, F.; Franceschi, C.; Lattanzio, F.; Antonicelli, R. Paraoxonase2 C311S polymorphism and low levels of HDL contribute to a higher mortality risk after acute myocardial infarction in elderly patients. Mol. Genet. Metab. 2009, 98, 314-318.
152. Jalilian, A.; Javadi, E.; Akrami, M.; Fakhrzadeh, H.; Heshmat, R.; Rahmani, M.; Bandarian, F. Association of cys 311 ser polymorphism of paraoxonase-2 gene with the risk of coronary artery disease. Arch. Iran Med.2008, 11, 544-549.
153. Rains, J.L.; Jain, S.K. Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med. 2011, 50, 567-575.
154. Koren-Gluzer, M.; Aviram, M.; Hayek, T. Paraoxonase1 (PON1) reduces insulin resistance in mice fed a high-fat diet, and promotes GLUT4 overexpression in myocytes, via the IRS-1/Akt pathway. Atherosclerosis 2013, 229, 71-78.
155. Amitai, G.; Gaidukov, L.; Adani, R.; Yishay, S.; Yacov, G.; Kushnir, M.; Teitlboim, S.; Lindenbaum, M.; Bel, P.; Khersonsky, O.; et al. Enhanced stereos elective hydrolysis of toxic organophosphates by directly evolved variants of mammalian serum paraoxonase. FEBS J. 2006, 273, 1906-1919.
156. Lee, S.J.; Kang, H.K.; Choi, Y.J.; Eum, W.S.; Park, J.; Choi, S.Y.; Kwon, H.Y. PEP-1-paraoxonase 1 fusion protein prevents cytokine-induced cell destruction and impaired insulin secretion in rat insulinoma cells. BMB Rep. 2018, 51, 538-543.
157. Shih, D.M.; Meng, Y.; Sallam, T.; Vergnes, L.; Shu, M.L.; Reue, K.; Tontonoz, P.; Fogelman, A.M.; Lusis, A.J.; Reddy, S.T. PON2 Deficiency Leads to Increased Susceptibility to Diet-Induced Obesity. Antioxidants 2019, 8, 19.
158. Golzari, M.H.; Javanbakht, M.H.; Ghaedi, E.; Mohammadi, H.; Djalali, M. Effect of Eicosapentaenoic Acid Supplementation on Paraoxonase 2 Gene Expression in Patients with Type 2 Diabetes Mellitus: ARandomized Double-blind Clinical Trial. Clin. Nutr. Res. 2019, 8, 17-27.
159. Dye, L.; Boyle, N.B.; Champ, C.; Lawton, C. The relationship between obesity and cognitive health and decline. Proc. Nutr. Soc. 2017, 76, 443-454.
160. Alaminos-Castillo, M.�?.; Ho-Plagaro, A.; García-Serrano, S.; Santiago-Fernandez, C.; Rodríguez-Pacheco, F.; Garrido-Sanchez, L.; Rodriguez, C.; Valdes, S.; Gonzalo, M.; Moreno-Ruiz, F.J.; et al. Increased PON lactonase activity in morbidly obese patients is associated with impaired lipid profile. Int. J. Clin. Pract. 2019, e13315.
161. Fülöp, P.; Harangi, M.; Seres, I.; Paragh, G. Paraoxonase-1 and adipokines: Potential links between obesity and atherosclerosis. Chem. Biol. Interact. 2016, 259, 388-393.
162. GomathI, P.; Iyer, A.C.; Murugan, O.S.; Sasikumar, S.; Raj, N.B.A.J.; Ganesan, D.; Nallaperumal, S.; Murugan, M.; Selvam, G.S. Association of paraoxonase-1 gene polymorphisms with insulin resistance in South Indian population. Gene 2018, 650, 55-59.
163. Pinizzotto, M.; Castillo, E.; Fiaux, M.; Temler, E.; Gaillard, R.C.; Ruiz, J. Paraoxonase2 polymorphisms are associated with nephropathy in Type II diabetes. Diabetologia 2001, 44, 104-107.
164. Qujeq, D.; Mahrooz, A.; Alizadeh, A.; Boorank, R. Paraoxonase-2 variants potentially influence insulin resistance, beta-cell function, and their interrelationships with alanine aminotransferase in type 2 diabetes. J. Res. Med. Sci. 2018, 23, 107.
165. Mahrooz, A.; Hashemi-Soteh, M.B.; Heydari, M.; Boorank, R.; Ramazani, F.; Mahmoudi, A.; Kianmehr, A.; Alizadeh, A. Paraoxonase 1 (PON1)-L55M among common variants in the coding region of the paraoxonase gene family may contribute to the glycemic control in type 2 diabetes. Clin. Chim. Acta 2018, 484, 40-46.
166. Shakeri, R.; Khajeniazi, S.; Marjani, A. Association between promoter polymorphism (-108C > T) of paraoxonase1 gene and it’s paraoxonase activity in patients with Type2 diabetes in northern Iran. Clin. Chim. Acta 2017, 474, 34-37.
167. Reed, T.T. Lipid peroxidation and neurodegenerative disease. Free Radic. Biol. Med. 2011, 51, 1302-1319.
168. Arimon, M.; Takeda, S.; Post, K.L.; Svirsky, S.; Hyman, B.T.; Berezovska, O. Oxidative stress and lipid peroxidation are upstream of amyloid pathology. Neurobiol. Dis. 2015, 84, 109-119.
169. Tindale, L.C.; Leach, S.; Spinelli, J.J.; Brooks-Wilson, A.R. Lipid and Alzheimer’s disease genes associated with healthy aging and longevity in healthy oldest-old. Oncotarget 2017, 8, 20612-20621.
170. Goswami, B.; Tayal, D.; Gupta, N.; Mallika, V. Paraoxonase: A multifaceted biomolecule. Clin. Chim. Acta 2009, 410, 1-12.
171. Saeidi, M.; Shakeri, R.; Marjani, A.; Khajeniazi, S. Alzheimer’s Disease and Paraoxonase 1 (PON1) Gene Polymorphisms. Open Biochem. J. 2017, 11, 47-55.
172. Kalia, L.V.; Lang, A.E. Parkinson’s disease. Lancet 2015, 386, 896-912.
173. Paul, K.C.; Sinsheimer, J.S.; Cockburn, M.; Bronstein, J.M.; Bordelon, Y.; Ritz, B. Organophosphate pesticides and PON1 L55M in Parkinson’s disease progression. Environ. Int. 2017, 107, 75-81.
174. Barim, A.O.; Aydin, S.; Colak, R.; Dag, E.; Deniz, O.; Sahin, I. Ghrelin, paraoxonase and arylesterase levels in depressive patients before and after citalopram treatment. Clin. Biochem. 2009, 42, 1076-1081.
175. Bednarska-Makaruk, M.; Rodo, M.; Szirkowiec, W.; Mossakowska, M.; Puzianowska-Kúznicka, M.; Skalska, A.; Zdrojewski, T.; Ryglewicz, D.; Wehr, H. Paraoxonase 1 activity and level of antibodies directed against oxidized low density lipoproteins in a group of elderly population in Poland-PolSenior study. Arch. Gerontol. Geriatr. 2015, 60, 153-161.
176. Bednarska-Makaruk, M.; Graban, A.; Wísniewska, A.; �?ojkowska,W.; Bochyńska, A.; Gugała-Iwaniuk, M.; Sławińska, K.; �?ugowska, A.; Ryglewicz, D.;Wehr, H. Association of adiponectin, leptin and resistin with inflammatory markers and obesity in dementia. Biogerontology 2017, 18, 561-580.
177. Correale, J.; Gaitán, M.I.; Ysrraelit, M.C.; Fiol, M.P. Progressive multiple sclerosis: From pathogenic mechanisms to treatment. Brain 2017, 140, 527-546.
178. Kirbas, A.; Kirbas, S.; Anlar, O.; Efe, H.; Yilmaz, A. Serum paraoxonase and arylesterase activity and oxidative status in patients with multiple sclerosis. J. Clin. Neurosci. 2013, 20, 1106-1109.
179. Castellazzi, M.; Trentini, A.; Romani, A.; Valacchi, G.; Bellini, T.; Bonaccorsi, G.; Fainardi, E.; Cavicchio, C.; Passaro, A.; Zuliani, G.; et al. Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases. Int. J. Biochem. Cell Biol. 2016, 81, 356-363.
180. Moghtaderi, A.; Hashemi, M.; Sharafaddinzadeh, N.; Dabiri, S.; Moazeni-Roodi, A.; Ramroodi, N.; Zolfaghari, M. Lack of association between paraoxonase 1 Q192R polymorphism and multiple sclerosis in relapse phase: A case-control study. Clin. Biochem. 2011, 44, 795-798.
181. Martínez, C.; García-Martín, E.; Benito-León, J.; Calleja, P.; Díaz-Sánchez, M.; Pisa, D.; Alonso-Navarro, H.; Ayuso-Peralta, L.; Torrecilla, D.; Agúndez, J.�?.; et al. Paraoxonase 1 polymorphisms are not related with the risk for multiple sclerosis. Neuromol. Med. 2010, 12, 217-223.
182. White, R.F.; Steele, L.; O’Callaghan, J.P.; Sullivan, K.; Binns, J.H.; Golomb, B.A.; Bloom, F.E.; Bunker, J.�?.; Crawford, F.; Graves, J.C.; et al. Recent research on GulfWar illness and other health problems in veterans of the 1991 Gulf War: Effects of toxicant exposures during deployment. Cortex 2016, 74, 449-475.
183. Hotopf, M.; Mackness, M.I.; Nikolaou, V.; Collier, D.A.; Curtis, C.; David, A.; Durrington, P.; Hull, L.; Ismail, K.; Peakman, M.; et al. Paraoxonase in Persian GulfWar veterans. J. Occup. Environ. Med. 2003, 45, 668-675.
184. Haley, R.W.; Billecke, S.; La Du, B.N. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in GulfWar veterans. Toxicol. Appl. Pharmacol. 1999, 157, 227-233.
185. Arenas, M.; Rodríguez, E.; Sahebkar, A.; Sabater, S.; Rizo, D.; Pallisé, O.; Hernández, M.; Riu, F.; Camps, J.; Joven, J. Paraoxonase-1 activity in patients with cancer: A systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 2018, 127, 6-14.
186. Bozan, N.; Demir, H.; Gürsoy, T.; Özkan, H.; Düzenli, U.; Sarıkaya, E.; Turan, M.; Kiroglu, A.F.; Çankaya, H. Alterations in oxidative stress markers in laryngeal carcinoma patients. J. Chin. Med. Assoc. 2018, 81, 811-815.
187. Tajiri, K.; Shimizu, Y. Liver physiology and liver diseases in the elderly. World J. Gastroenterol. 2013, 19, 8459-8467.
188. Yu, Z.; Ou, Q.; Chen, F.; Bi, J.; Li, W.; Ma, J.; Wang, R.; Huang, X. Evaluation of the prognostic value of paraoxonase 1 in the recurrence and metastasis of hepatocellular carcinoma and establishment of a liver-specific predictive model of survival. J. Transl. Med. 2018, 16, 327.
189. Ahmed, N.S.; Shafik, N.M.; Elraheem, O.A.; Abou-Elnoeman, S.E. Association of paraoxonase-1(Q192R and L55M) gene polymorphisms and activity with colorectal cancer and effect of surgical intervention. Asian Pac. J. Cancer Prev. 2015, 16, 803-809.
190. Wu, J.; Fang, M.; Zhou, X.; Zhu, B.; Yang, Z. Paraoxonase 1 gene polymorphisms are associated with an increased risk of breast cancer in a population of Chinese women. Oncotarget 2017, 8, 25362-25371.
191. Krüger, M.; Pabst, A.M.; Al-Nawas, B.; Horke, S.; Moergel, M. Paraoxonase-2 (PON2) protects oral squamous cell cancer cells against irradiation-induced apoptosis. J. Cancer Res. Clin. Oncol. 2015, 141, 1757-1766.
192. Pai, S.G.; Carneiro, B.A.; Mota, J.M.; Costa, R.; Leite, C.A.; Barroso-Sousa, R.; Kaplan, J.B.; Chae, Y.K.; Giles, F.J. Wnt/beta-catenin pathway: Modulating anticancer immune response. J. Hematol. Oncol. 2017, 10, 101.
193. Zhan, T.; Rindtorff, N.; Boutros, M. Wnt signaling in cancer. Oncogene 2017, 36, 1461-1473.
194. Krüger,M.; Amort, J.;Wilgenbus, P.; Helmstädter, J.P.; Grechowa, I.; Ebert, J.; Tenzer, S.; Moergel, M.;Witte, I.; Horke, S. The anti-apoptotic PON2 protein is Wnt/β-catenin-regulated and correlates with radiotherapy resistance in OSCC patients. Oncotarget 2016, 7, 51082-51095.
195. Shakhparonov, M.I.; Antipova, N.V.; Shender, V.O.; Shnaider, P.V.; Arapidi, G.P.; Pestov, N.B.; Pavlyukov, M.S. Expression and Intracellular Localization of Paraoxonase 2 in Different Types of Malignancies. Acta Nat.2018, 10, 92-99.
196. Schweikert, E.M.; Devarajan, A.;Witte, I.;Wilgenbus, P.; Amort, J.; Förstermann, U.; Shabazian, A.; Grijalva, V.; Shih, D.M.; Farias-Eisner, R.; et al. PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death. Cell Death Differ. 2012, 19, 1549-1560.
197. Kim, E.K.; Choi, E.J. Compromised MAPK signaling in human diseases: An update. Arch. Toxicol. 2015, 89, 867-882.
198. Baharudin, R.; Ab Mutalib, N.S.; Othman, S.N.; Sagap, I.; Rose, I.M.; Mohd Mokhtar, N.; Jamal, R. Identification of Predictive DNA Methylation Biomarkers for Chemotherapy Response in Colorectal Cancer. Front. Pharmacol. 2017, 8, 47.
199. Shui, I.M.; Wong, C.J.; Zhao, S.; Kolb, S.; Ebot, E.M.; Geybels, M.S.; Rubicz, R.; Wright, J.L.; Lin, D.W.; Klotzle, B.; et al. Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes. Cancer 2016, 122, 2168-2177.
200. Cakatay, U.; Kayali, R.; Uzun, H. Relation of plasma protein oxidation parameters and paraoxonase activity in the ageing population. Clin. Exp. Med. 2008, 8, 51-57.
201. Saruhan, E.; Olgun, A.; Oztürk, K.; Akman, S.; Erbil, M.K. Age-related paraoxonase activity changes in Turkish population. Ann. N Y. Acad. Sci. 2007, 1100, 218-222.
202. Lescai, F.; Marchegiani, F.; Franceschi, C. PON1 is a longevity gene: Results of a meta-analysis. Ageing Res. Rev. 2009, 8, 277-284.
203. Rea, I.M.; McKeown, P.P.; McMaster, D.; Young, I.S.; Patterson, C.; Savage, M.J.; Belton, C.; Marchegiani, F.; Olivieri, F.; Bonafe, M.; et al. Paraoxonase polymorphisms PON1 192 and 55 and longevity in Italian centenarians and Irish nonagenarians. A Pool. Anal. Exp. Gerontol. 2004, 39, 629-635.
204. Goulet, E.D.; Hassaine, A.; Dionne, I.J.; Gaudreau, P.; Khalil, A.; Fulop, T.; Shatenstein, B.; Tessier, D.; Morais, J.A. Frailty in the elderly is associated with insulin resistance of glucose metabolism in the postabsorptive state only in the presence of increased abdominal fat. Exp. Gerontol. 2009, 44, 740-744.
205. Summerbell, J.;Wynne, H.; Hankey, C.R.;Williams, F.M. The effect of age and frailty upon blood esterase activities and their response to dietary supplementation. Br. J. Clin. Pharmacol. 1993, 36, 399-404.
206. Bulló, M.; Lamuela-Raventós, R.; Salas-Salvadó, J. Mediterranean diet and oxidation: Nuts and olive oil as important sources of fat and antioxidants. Curr. Top. Med. Chem. 2011, 11, 1797-1810.
207. Lou-Bonafonte, J.M.; Gabás-Rivera, C.; Navarro, M.A.; Osada, J. PON1 and Mediterranean Diet. Nutrients 2015, 7, 4068-4092.
208. Loued, S.; Berrougui, H.; Componova, P.; Ikhlef, S.; Helal, O.; Khalil, A. Extra-virgin olive oil consumption reduces the age-related decrease in HDL and paraoxonase 1 anti-inflammatory activities. Br. J. Nutr. 2013, 110, 1272-1284.
209. Vamecq, J.; Andreoletti, P.; El Kebbaj, R.; Saih, F.E.; Latruffe, N.; El Kebbaj, M.H.S.; Lizard, G.; Nasser, B.; Cherkaoui-Malki, M. Peroxisomal Acyl-CoA Oxidase Type 1: Anti-Inflammatory and Anti-Aging Properties with a Special Emphasis on Studies with LPS and Argan Oil as a Model Transposable to Aging. Oxid. Med. Cell. Longev. 2018, 2018, 6986984.
210. Cherki, M.; Derouiche, A.; Drissi, A.; El Messal, M.; Bamou, Y.; Idrissi-Ouadghiri, A.; Khalil, A.; Adlouni, A. Consumption of argan oil may have an antiatherogenic effect by improving paraoxonase activities and antioxidant status: Intervention study in healthy men. Nutr. Metab. Cardiovasc. Dis. 2005, 15, 352-360.